source
- Vaxcyte's next-gen pneumococcal vaccine matches leading shots in Phase 3 trialVaxcyte reported that its experimental pneumococcal vaccine, VAX-31, achieved its primary efficacy goals in the first of three Phase 3 studies. In adults aged 50 and older, the vaccine performed o…
- Pfizer's experimental eczema drug tilrekimig shows strong skin clearance in Phase 2 trialPfizer reported that its three‑pronged antibody, tilrekimig, met the primary endpoint of its Phase 2 study in patients with moderate to severe atopic dermatitis. After 16 weeks, a significantly hig…